Literature DB >> 16498609

Neuroproteomics in neurotrauma.

Andrew K Ottens1, Firas H Kobeissy, Erin C Golden, Zhiqun Zhang, William E Haskins, Su-Shing Chen, Ronald L Hayes, Kevin K W Wang, Nancy D Denslow.   

Abstract

Neurotrauma in the form of traumatic brain injury (TBI) afflicts more Americans annually than Alzheimer's and Parkinson's disease combined, yet few researchers have used neuroproteomics to investigate the underlying complex molecular events that exacerbate TBI. Discussed in this review is the methodology needed to explore the neurotrauma proteome-from the types of samples used to the mass spectrometry identification and quantification techniques available. This neuroproteomics survey presents a framework for large-scale protein research in neurotrauma, as applied for immediate TBI biomarker discovery and the far-reaching systems biology understanding of how the brain responds to trauma. Ultimately, knowledge attained through neuroproteomics could lead to clinical diagnostics and therapeutics to lessen the burden of neurotrauma on society. Copyright 2006 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16498609     DOI: 10.1002/mas.20073

Source DB:  PubMed          Journal:  Mass Spectrom Rev        ISSN: 0277-7037            Impact factor:   10.946


  14 in total

1.  Minimal traumatic brain injury induce apoptotic cell death in mice.

Authors:  V Tashlykov; Y Katz; A Volkov; V Gazit; S Schreiber; O Zohar; C G Pick
Journal:  J Mol Neurosci       Date:  2008-07-24       Impact factor: 3.444

Review 2.  Current status of fluid biomarkers in mild traumatic brain injury.

Authors:  Jacqueline R Kulbe; James W Geddes
Journal:  Exp Neurol       Date:  2015-05-14       Impact factor: 5.330

Review 3.  Biomarkers of mild traumatic brain injury in cerebrospinal fluid and blood.

Authors:  Henrik Zetterberg; Douglas H Smith; Kaj Blennow
Journal:  Nat Rev Neurol       Date:  2013-02-12       Impact factor: 42.937

Review 4.  Post-genomics nanotechnology is gaining momentum: nanoproteomics and applications in life sciences.

Authors:  Firas H Kobeissy; Basri Gulbakan; Ali Alawieh; Pierre Karam; Zhiqun Zhang; Joy D Guingab-Cagmat; Stefania Mondello; Weihong Tan; John Anagli; Kevin Wang
Journal:  OMICS       Date:  2014-01-10

5.  Metabolic crisis after traumatic brain injury is associated with a novel microdialysis proteome.

Authors:  R Lakshmanan; J A Loo; T Drake; J Leblanc; A J Ytterberg; D L McArthur; M Etchepare; P M Vespa
Journal:  Neurocrit Care       Date:  2010-06       Impact factor: 3.210

6.  Neuroproteomics: a biochemical means to discriminate the extent and modality of brain injury.

Authors:  Andrew K Ottens; Liliana Bustamante; Erin C Golden; Changping Yao; Ronald L Hayes; Kevin K W Wang; Frank C Tortella; Jitendra R Dave
Journal:  J Neurotrauma       Date:  2010-10-09       Impact factor: 5.269

7.  Involvement of acidic fibroblast growth factor in spinal cord injury repair processes revealed by a proteomics approach.

Authors:  Ming-Chu Tsai; Li-Fen Shen; Huai-Sheng Kuo; Henrich Cheng; Kin-Fu Chak
Journal:  Mol Cell Proteomics       Date:  2008-05-14       Impact factor: 5.911

8.  Microwave & magnetic (M2) proteomics reveals CNS-specific protein expression waves that precede clinical symptoms of experimental autoimmune encephalomyelitis.

Authors:  Itay Raphael; Swetha Mahesula; Anjali Purkar; David Black; Alexis Catala; Jonathon A L Gelfond; Thomas G Forsthuber; William E Haskins
Journal:  Sci Rep       Date:  2014-09-03       Impact factor: 4.379

Review 9.  Systematic review of clinical research on biomarkers for pediatric traumatic brain injury.

Authors:  Linda Papa; Michelle M Ramia; Jared M Kelly; Stephen S Burks; Artur Pawlowicz; Rachel P Berger
Journal:  J Neurotrauma       Date:  2013-02-15       Impact factor: 5.269

10.  Integration of proteomics, bioinformatics, and systems biology in traumatic brain injury biomarker discovery.

Authors:  J D Guingab-Cagmat; E B Cagmat; R L Hayes; J Anagli
Journal:  Front Neurol       Date:  2013-05-31       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.